{"id":734,"date":"2023-10-11T19:30:49","date_gmt":"2023-10-12T02:30:49","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=734"},"modified":"2024-03-21T21:40:54","modified_gmt":"2024-03-22T04:40:54","slug":"remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh\/remarkable-progress-in-clinical-trials-cbt-009-and-cbt-004\/","title":{"rendered":"\u4e34\u5e8a\u8bd5\u9a8c\u53d6\u5f97\u663e\u8457\u8fdb\u5c55\uff1aCBT-009\u548cCBT-004"},"content":{"rendered":"<p id=\"ember1207\" class=\"ember-view reader-content-blocks__paragraph\"><strong>Cloudbreak Pharma\uff08\u62e8\u5eb7\u89c6\u4e91\uff09\u6b23\u7136\u5ba3\u5e03\u00a0<\/strong><\/p>\n<ol>\n<li>CBT-009\u662f\u6211\u4eec\u7528\u4e8e\u6cbb\u7597\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u963f\u6258\u54c1\u65b0\u578b\u773c\u79d1\u5236\u5242\uff0c\u5df2\u4e0eFDA\u8fbe\u6210\u534f\u8bae\uff0c\u5c06\u5728\u7f8e\u56fd\u8fdb\u51653\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/li>\n<li>\u6211\u4eec\u5df2\u5411FDA\u63d0\u4ea4\u4e86\u5728\u7f8e\u56fd\u8fdb\u884c2\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7533\u8bf7\uff0c\u4ee5\u6d4b\u8bd5\u7528\u4e8e\u6cbb\u7597\u8840\u7ba1\u5316\u5c0f\u53f6\u7684\u9996\u521b\u5019\u9009\u836f\u7269CBT-004\u3002<\/li>\n<\/ol>\n<h2 id=\"ember1212\" class=\"ember-view\">CBT-009\u5df2\u4e0eFDA\u8fbe\u6210\u534f\u8bae\uff0c\u5728\u7f8e\u56fd\u8fdb\u51653\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/h2>\n<p id=\"ember1213\" class=\"ember-view reader-content-blocks__paragraph\">\u62e8\u5eb7\u89c6\u4e91\u7684\u6838\u5fc3\u4ea7\u54c1\u4e4b\u4e00CBT-009\u6ef4\u773c\u6db2\u5df2\u4e8e2023\u5e749\u670821\u65e5\u83b7\u5f97\u7f8e\u56fd\u836f\u76d1\u5c40\u7684\u8bb8\u53ef\uff0c \u5c06\u5728\n\u7f8e\u56fd\u7387\u5148\u8fdb\u884c\u4e34\u5e8a3\u671f\u7684\u7814\u7a76\u3002<\/p>\n<p id=\"ember1214\" class=\"ember-view reader-content-blocks__paragraph\">\u963f\u6258\u54c1\u662f\u4e2d\u56fd\u56fd\u5bb6\u536b\u751f\u5065\u5eb7\u59d4\u53d1\u5e03\u7684\u300a \u513f\u7ae5\u9752\u5c11\u5e74\u8fd1\u89c6\u9632\u63a7\u9002\u5b9c\u6280\u672f\u6307\u5357\u300b \u4e2d\u63a8\u8350\u7684\u6cbb\u7597\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u836f\u7269\u3002 \u76ee\u524d\uff0c \u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u662f\u552f\u4e00\u88ab\u8bc1\u660e\u80fd\u6301\u7eed\u6709\u6548\u51cf\u7f13\u8fd1\u89c6\u8fdb\u5c55\u7684\u6297\u80c6\u78b1\u836f\u7269\u6cbb\u7597\u9009\u62e9\u3002 \u7136\u800c\uff0c \u7531\u4e8e\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u5728\u6c34\u6027\u5236\u5242\u4e2d\u4e0d\u7a33\u5b9a\uff0c \u4fdd\u8d28\u671f\u6709\u9650\uff0c \u5bfc\u81f4\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u672a\u80fd\u88ab\u66f4\u5e7f\u6cdb\u7684\u8ba4\u53ef\u4e3a\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u6cbb\u7597\u65b9\u5f0f\u3002 \u56e0\u800c\uff0c \u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u7684\u4e0d\u7a33\u5b9a\u6027\u957f\u671f\u4ee5\u6765\u4e00\u76f4\u662f\u5546\u4e1a\u5316\u7684\u6280\u672f\u969c\u788d\u3002<\/p>\n<p id=\"ember1215\" class=\"ember-view reader-content-blocks__paragraph\">\u963f\u6258\u54c1\u662f\u4e2d\u56fd\u56fd\u5bb6\u536b\u751f\u5065\u5eb7\u59d4\u53d1\u5e03\u7684\u300a\u513f\u7ae5\u9752\u5c11\u5e74\u8fd1\u89c6\u9632\u63a7\u9002\u5b9c\u6280\u672f\u6307\u5357\u300b\u4e2d\u63a8\u8350\u7684\u6cbb\u7597\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u836f\u7269\u3002\u76ee\u524d\uff0c\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u662f\u552f\u4e00\u88ab\u8bc1\u660e\u80fd\u6301\u7eed\u6709\u6548\u51cf\u7f13\u8fd1\u89c6\u8fdb\u5c55\u7684\u6297\u80c6\u78b1\u836f\u7269\u6cbb\u7597\u9009\u62e9\u3002\u7136\u800c\uff0c\u7531\u4e8e\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u5728\u6c34\u6027\u5236\u5242\u4e2d\u4e0d\u7a33\u5b9a\uff0c\u4fdd\u8d28\u671f\u6709\u9650\uff0c\u5bfc\u81f4\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u672a\u80fd\u88ab\u66f4\u5e7f\u6cdb\u7684\u8ba4\u53ef\u4e3a\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u6cbb\u7597\u65b9\u5f0f\u3002\u56e0\u800c\uff0c\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u7684\u4e0d\u7a33\u5b9a\u6027\u957f\u671f\u4ee5\u6765\u4e00\u76f4\u662f\u5546\u4e1a\u5316\u7684\u6280\u672f\u969c\u788d\u3002<\/p>\n<p id=\"ember1216\" class=\"ember-view reader-content-blocks__paragraph\">\u62e8\u5eb7\u89c6\u4e91\u5728\u56fd\u9645\u9996\u521b\u65b0\u578b\u975e\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u5242CBT-009\uff0c \u4e0e\u73b0\u6709\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u76f8\u6bd4\uff0c \u5236\u5242\u7a33\u5b9a\u6027\u5927\u5e45\u5ea6\u63d0\u9ad8\uff0c \u53ef\u4ee5\u663e\u8457\u51cf\u5c11\u963f\u6258\u54c1\u7684\u964d\u89e3\uff0c \u4ece\u800c\u51cf\u5c11\u6742\u8d28\u7684\u4ea7\u751f\uff0c \u4f7f\u5f97CBT-009\u5728\u5ba4\u6e29\u751a\u81f3\u9ad8\u6e29\u4e0b\u53ef\u4ee5\u957f\u671f\u4fdd\u5b58\u3002 CBT-009\u6ef4\u773c\u6db2\u672c\u8eab\u5177\u6709\u9632\u6b62\u7ec6\u83cc\u751f\u957f\u7684\u80fd\u529b\uff0c \u56e0\u6b64\u4e0d\u9700\u8981\u989d\u5916\u6dfb\u52a0\u9632\u8150\u5242\u6216\u8fdb\u884c\u7279\u6b8a\u5355\u5242\u91cf\u5305\u88c5\u3002 \u975e\u6c34\u6027\u963f\u6258\u54c1\u6ef4\u773c\u6db2CBT-009\u6240\u9700\u4f7f\u7528\u7684\u5242\u91cf\u6bd4\u73b0\u6709\u6c34\u6027\u6ef4\u773c\u6db2\u4f4e\uff0c \u53ef\u4ee5\u5747\u5300\u5206\u5e03\u5728\u6cea\u6db2\u4e0a\u4ece\u800c\u589e\u52a0\u4e86\u963f\u6258\u54c1\u5728\u773c\u8868\u505c\u7559\u65f6\u95f4\u53ca\u63d0\u9ad8\u751f\u7269\u5229\u7528\u5ea6\u3002 \u6b64\u5916\uff0c CBT-009\u6ef4\u773c\u6db2\u5177\u5907\u773c\u90e8\u8212\u9002\u6db2\u7684\u529f\u80fd\uff0c \u60a3\u8005\u4f53\u9a8c\u611f\u4f18\u5f02\uff0c \u5c06\u4f1a\u663e\u8457\u63d0\u9ad8\u9752\u5c11\u5e74\u60a3\u8005\u533b\u4ece\u6027\u3002<\/p>\n<p id=\"ember1217\" class=\"ember-view reader-content-blocks__paragraph\">\u4f5c\u4e3a\u62e8\u5eb7\u89c6\u4e91\u7684\u6838\u5fc3\u4ea7\u54c1\u4e4b\u4e00\uff0c \u65e0\u6c34\uff0c \u65e0\u9632\u8150\u5242\uff0c \u8212\u9002\u7684\u591a\u5242\u91cf\u5305\u88c5CBT-009\u6ef4\u773c\u6db2\u9884\u8ba1\u5c06\u663e\u8457\u63d0\u9ad8\u60a3\u8005\u7684\u8010\u53d7\u6027\u3001 \u5b89\u5168\u6027\u3001 \u533b\u4ece\u6027\u548c\u4ea7\u54c1\u7a33\u5b9a\u6027\u3002 \u5728\u7f8e\u56fd\u83b7\u6279III\u671f\u4e34\u5e8a\u8bb8\u53ef\u662f\u5b9e\u73b0\u8be5\u836f\u7269\u5546\u4e1a\u5316\u7684\u4e00\u4e2a\u91cd\u8981\u91cc\u7a0b\u7891\uff0c \u4e5f\u662f\u516c\u53f8\u7ee7\u6cbb\u7597\u7ffc\u72b6\u80ec\u8089\u65b0\u836fCBT-001\u540e\u7b2c\u4e8c\u4e2a\u81ea\u4e3b\u521b\u65b0\u4ea7\u54c1\u83b7\u6279\u8fdb\u5165\u7f8e\u56fd\u4e34\u5e8a3\u671f\u3002<\/p>\n<h2 id=\"ember1219\" class=\"ember-view\">CBT-004\u5df2\u5411FDA\u63d0\u4ea4\u4e86\u5728\u7f8e\u56fd\u8fdb\u884c2\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7533\u8bf7\u3002<\/h2>\n<p id=\"ember1220\" class=\"ember-view reader-content-blocks__paragraph\">CBT-004\u6ef4\u773c\u6db2\u5df2\u4e8e2023\u5e749\u670829\u65e5\u9012\u4ea4\u7f8e\u56fd\u836f\u76d1\u5c40\uff0c \u7533\u8bf7\u6cbb\u7597\u5145\u8840\u6027\u7ed3\u819c\u9ec4\u6591\u7684\u4e34\u5e8aII\u671f\u7814\u7a76\u3002 CBT-004\u662f\u4e00\u79cd\u5c0f\u5206\u5b50\u591a\u6fc0\u9176\u6291\u5236\u5242\uff0c \u5728\u975e\u4e34\u5e8a\u836f\u6548\u52a8\u7269\u6a21\u578b\u4ee5\u53ca\u52a8\u7269\u6bd2\u7406\u5b9e\u9a8c\u4e2d\u5747\u663e\u793a\u51fa\u826f\u597d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002 \u6839\u636eFrost &amp;Sullivan\u62a5\u544a\uff0c \u76ee\u524d\u5168\u7403\u5c1a\u65e0\u83b7\u6279\u51c6\u7684\u6cbb\u7597\u5145\u8840\u6027\u7ed3\u819c\u9ec4\u6591\u7684\u836f\u7269\u7597\u6cd5\u3002 \u800c\u5728\u5168\u7403\u8303\u56f4\u5185\uff0c2022\u5e74\u7ed3\u819c\u9ec4\u6591\u60a3\u8005\u4eba\u6570\u8fbe\u523011.496\u4ebf\uff0c 2018\u5e74\u81f32022\u5e74\u590d\u5408\u5e74\u589e\u957f\u7387\u4e3a1.2%\u3002 \u9884\u8ba12027\u5e74\u5c06\u8fbe\u523012.171\u4ebf\uff0c 2032\u5e74\u5c06\u8fbe\u523012.838\u4ebf\uff0c2022\u5e74\u52302027\u5e74\u590d\u5408\u5e74\u589e\u957f\u7387\u4e3a1.1% \uff0c 2027\u5e74\u52302032\u5e74\u590d\u5408\u589e\u957f\u7387\u4e3a1.1%\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>We are proud to announce that\u00a0 CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA to enter into Phase 3 clinical trial in the USA. We have submitted our application to FDA for conducting a Phase 2 clinical trial in the United States to test [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":736,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-734","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/comments?post=734"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/734\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media\/736"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media?parent=734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/categories?post=734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/tags?post=734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}